Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
Season 6, Episode 13, Jul 16, 2023, 11:00 AM
Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Show notes
To learn more about the adalimumab products that have launched in the US so far, click here, here, here, or here.
Crohn's & Colitis Educational Resources: